News & Events

Castle Biosciences Presents Three New Clinical Studies at ASCO 2017 Highlighting the Accuracy and Performance of the DecisionDx-Melanoma Gene Expression Profile Test for Cutaneous Melanoma

Cox Multivariate Regression Analysis for DMFS in All Stage III PatientsChicago, IL – June 5, 2017 – Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced that three abstracts detailing results from studies of DecisionDx®-Melanoma were presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago, IL from June 2-6. Presentations included an interim analysis of a prospective, multicenter registry study, test performance in Stage III cutaneous (skin) melanoma patients and an analysis more »

Study Demonstrates Significant and Risk-Appropriate Clinical Impact of DecisionDx-Melanoma Test Results on Patient Management Decisions

Friendswood, TX – May 15, 2017 – Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced the publication of results from a study evaluating the clinical impact of its gene expression profile (GEP) test DecisionDx®-Melanoma. The test uses tumor biology to provide an individual risk of recurrence in cutaneous (skin) melanoma patients. The paper titled, “Impact of a 31-gene Expression Profiling Test for Cutaneous Melanoma on Dermatologists’ Clinical Management more »

Castle Biosciences’ DecisionDx-Melanoma Test Shown to be a Significant Predictor of Distant Metastasis in Elderly Patients with Melanoma

Friendswood, TX–March 20, 2017 Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced that studies evaluating the prognostic performance and clinical impact of the DecisionDx®-Melanoma gene expression profile (GEP) test, including a cohort of elderly patients and four independent studies, were presented during the 70th Society of Surgical Oncology Annual Cancer Symposium (SSO) held in Seattle, WA from March 15-18. “We know that there is a decline in the rate of more »

Study Demonstrates that DecisionDx-Melanoma Test Improves Identification of High Risk Skin Melanoma When Used with AJCC Outcome Prediction Tool

GEP classification and AJCC predictions of risk (n=205)Friendswood, TX – January 23, 2017 – Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced the publication of results from a study comparing and combining risk prediction using DecisionDx®-Melanoma, the Company’s gene expression profile (GEP) test used to predict risk of metastasis in cutaneous melanoma (CM) patients, and the American Joint Committee on Cancer’s (AJCC’s) clinical staging system using the Individualized Melanoma Patient Outcome Prediction Tool. The AJCC more »

Castle Biosciences Announces Data Presentations at the Association for Molecular Pathology 2016 Annual Meeting with Gene Expression Profile Tests for Uveal and Cutaneous Melanoma

Friendswood, TX – November 14, 2016 – Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced results from studies evaluating clinical experience with gene expression profile (GEP) tests DecisionDx®-Melanoma and DecisionDx®-UM. In the studies, both GEP tests demonstrated a high technical success rate with robust, reproducible and reliable performance. The data were presented in poster sessions at the Association for Molecular Pathology (AMP) 2016 Annual Meeting, which was held more »

Older Entries »
Know Your Risk

DecisionDx-Melanoma

A new genomic test is designed to predict if your cancer is at high risk of spreading, based on your tumor’s biology. Watch Video
Talk to Your Doctor
Decide with your doctor if DecisionDx-Melanoma is right for you. Download PDF
Gene Test Validation